Europe

European healthcare investor EQT Life Sciences has closed its inaugural LSP Dementia Fund at €260 million euros, beating its target of €100 million.

Sofinnova Partners, a European life sciences venture capital firm, has launched a new investment strategy focused on digital medicine.

Playfair Capital, a seed investor focused on the UK and Europe, has raised $70 million for its third tech-focused pre-seed fund, growing its overall fundraising total to $140 million.

SR One Capital Management, a transatlantic biotech VC firm that spun out of GlaxoSmithKline, has closed on more than $600 million for its second fund, beating its $500 million target.

SWEN’s Blue Ocean Fund is one of at least four funds that have collectively raised more than $400m to preserve ocean health.

Making up for several years of underinvestment in venture capital, the California Public Employees’ Retirement System committed more than $1.1bn to 15 venture vehicles last year.

Headline’s Deepdive technology helps the firm discover insights – and spot potential fraud – by analyzing a company’s raw financial and usage data.

While many investors gave into FOMO and took shortcuts in their due diligence, Thomvest leaned into a more careful approach.

IP attorneys are spending lots of time making sure VC-backed start-ups have the freedom to operate and get products to market.

Cautionary tales of governance failures and heightened litigation risk have some VCs rethinking their due diligence processes.